Omics approaches and advances in therapeutic modalities have the potential to identify novel fibrotic pathways and unleash innovative cross-organ antifibrotic therapies.
Fibrosis is a major cause of mortality and morbidity worldwide with limited therapeutic options. Our understanding of fibrosis has significantly improved and led to the identification of “core” fibrogenic mechanisms that fuel a self-sustaining vicious cycle following the initial insult. The fibrotic niche is the result of complex cellular and molecular interactions that need to be disrupted to achieve transformational therapies. In this Review, we describe the current understanding of fibrogenic mechanisms, the progress and limitations of omics approaches in the identification of novel fibrotic pathways, and advances in therapeutic modalities that all together have the potential to unleash innovative cross-organ antifibrotic therapies.
Lebeaupin et al. (Mon,) conducted a review in Fibrosis. Omics approaches and cross-organ antifibrotic therapies was evaluated. Omics approaches and advances in therapeutic modalities have the potential to identify novel fibrotic pathways and unleash innovative cross-organ antifibrotic therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: